

## Special Issue

# Recent Advances in Fragment-Based Drug Discovery

### Message from the Guest Editors

Fragment-based drug discovery (FBDD) has emerged as a powerful strategy in modern drug discovery, with successful applications across a wide range of targets including proteins, RNA, and macromolecular complexes. To date, several FDA-approved drugs and numerous clinical candidates have been derived from FBDD. With the rapid integration of AI-driven approaches in structural biology and drug discovery, FBDD is poised to play an even more pivotal role in drug discovery, particularly when combined with complementary technologies.

This Special Issue aims to highlight the latest advances and future directions in FBDD. By bringing together diverse perspectives, this Special Issue will showcase how FBDD continues to evolve as a central pillar of drug discovery.

We look forward to receiving your contributions.

---

### Guest Editors

Dr. Congbao Kang

A-STAR, Experimental Therapeutics Centre, Singapore City, Singapore

Dr. Weijun Xu

Agency for Science, Technology and Research, Singapore, Singapore City, Singapore

---

### Deadline for manuscript submissions

30 September 2026



## Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/si/254049](https://mdpi.com/si/254049)

*Molecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).